BiotechTube
AivoCode

AivoCode

San Francisco, United States· Est.
aivocode.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AivoCode is a private, preclinical-stage biotech company founded in 2020 and based in San Francisco, CA. The company is developing a novel platform to discover molecular 'zip codes' that enable targeted delivery of neuroprotective and anti-inflammatory therapeutics to specific diseased areas of the brain and eye. Its pipeline includes a lead neuroprotection candidate and a therapeutic antibody program for an early Alzheimer's target, positioning it to address significant unmet needs in neurology and ophthalmology. The company is led by a team with deep experience in drug delivery, neuroscience, and startup ventures.

NeurologyOphthalmologyNeurodegenerative Diseases

Technology Platform

Unbiased screening platform to identify molecular 'zip codes' (unique markers) specific to diseased regions or cell types in the brain and central nervous system, enabling targeted delivery of therapeutics.

Opportunities

The platform addresses a major bottleneck in neurology—delivering drugs effectively to the brain—which, if successful, could be applied to a wide range of CNS disorders.
The early focus on vascular dysfunction in Alzheimer's and neuroprotection in glaucoma targets significant unmet needs in large, growing markets with limited disease-modifying treatments.

Risk Factors

High technical risk associated with validating a novel targeting platform in the complex CNS environment.
As a preclinical, private company, it faces significant financing risk and dilution to advance its programs.
Intense competition in its chosen therapeutic areas from large, well-resourced entities.

Competitive Landscape

Competes with numerous biopharma companies developing neuroprotective agents (e.g., Biogen, AstraZeneca) and novel Alzheimer's therapies (e.g., Eisai, Lilly, Roche). In targeted CNS delivery, it faces competition from platform companies like Denali Therapeutics and Ikano Therapeutics. Its differentiation lies in its specific 'zip code' discovery approach championed by Dr. Ruoslahti.

More companies in Neuroscience & CNS →More companies in United States →